Since tumor-derived nucleic acids rarely exist existing in patient’s plasma, pre-analytical steps, especially selecting target materials that harbored relatively abundant mutant alleles and extracted them using an appropriated method, are important to improve the sensitivity of EGFR test using patient’s plasma with low levels of mutant alleles. The gene discussed is EGFR; the disease is neoplasm.